

## **Astellas Announces Acquisition of Own Shares**

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, November 1, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

### Particulars

1. Reasons for the acquisition of own shares  
To improve capital efficiency and shareholder return.
  
  2. Contents of acquisition
    - (1) Class of shares to be acquired: Common stock of the Company
    - (2) Total number of shares to be acquired: Up to 5.3 million shares  
(The percentage compared to the total number of shares outstanding: 1.17%)
    - (3) Aggregate amount of acquisition cost: Up to 30 billion yen
    - (4) Period of acquisition: From November 5, 2013 to December 16, 2013
- (Reference)  
The status of treasury stock as of September 30, 2013:  
Total number of shares outstanding: 451,217,914 shares  
Number of treasury stock: 5,746,721 shares

#####

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 <a href="http://www.astellas.com/en">http://www.astellas.com/en</a>